세계의 폴리뉴클레오티드 주사제 시장 규모, 점유율, 동향 분석 : 용도별, 최종 용도별, 지역별, 부문별(2025-2030년)

Polynucleotides Injectable Market Size, Share & Trends Analysis Report By Application (Eyes, Lips, Forehead, Jawline & Cheekbones), By End-use (MedSpas, Aesthetic & Cosmetic Centers), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

폴리뉴클레오티드 주사제 시장 규모와 동향 :

세계의 폴리뉴클레오티드 주사제 시장 규모는 2024년에 1억 2,760만 달러로 추계되며, 2025-2030년에 CAGR 15.1%로 성장할 것으로 예측됩니다.

PMTA Journal이 2024년 3월에 발표한 논문에 따르면 폴리뉴클레오티드 주사는 피부 회춘, 맞춤형 의료, 연구개발(R&D)에 대한 투자에 대한 수요 증가와 함께 시장 성장의 원동력으로 작용하고 있습니다. 피부, 모발 및 기타 조직에 대한 유익한 효과로 인해 메디컬 에스테틱 분야에서 각광을 받고 있습니다.

첨단 피부 회춘 치료에 대한 수요 증가는 폴리뉴클레오티드 주사제 산업의 주요 원동력이 되고 있습니다. 사람들이 잔주름, 주름, 피부 처짐과 같은 노화 징후에 대한 보다 효과적인 해결책을 찾으면서 폴리뉴클레오티드와 같은 새로운 주사제 치료에 대한 관심이 급증하고 있습니다. 예를 들어 Dermatologic Therapy 저널에 게재된 최근 연구에 따르면 폴리뉴클레오티드 주사는 30-40대 환자의 피부톤, 잔주름, 피부 탄력, 보습을 개선하는 것으로 나타났습니다.

맞춤형 의료에 대한 관심이 높아지면서 시장 성장에 기여하고 있습니다. 의료 프로바이더와 환자 모두 피부 회춘에 대한 맞춤형 접근 방식을 원하고 있으며, 폴리뉴클레오티드의 체내 자연 콜라겐 생성 및 세포 재생을 자극하는 능력은 인기 있는 선택이 되고 있습니다. 이러한 추세는 특히 개인 맞춤형 미용 치료에 대한 수요 증가로 두드러지게 나타나고 있으며, 향후 시장 확대가 예상됩니다.

마지막으로 디지털 이미지 및 자동 주사 시스템과 같은 혁신적인 기술의 통합은 폴리뉴클레오티드 주사제 산업을 더욱 발전시키고 있습니다. 이러한 발전은 폴리뉴클레오티드 주사의 정확성, 일관성, 안전성을 향상시켜 의료진과 환자들에게 더욱 매력적으로 다가갈 수 있도록 했습니다. 미용 산업이 계속 진화하는 가운데, 첨단 기술을 도입하는 것은 폴리뉴클레오티드 주사제 산업의 중요한 원동력이 될 것으로 예상됩니다. 예를 들어 2022년 런던의 펄스 라이트 클리닉(Pulse Light Clinic)은 피부 보습과 탄력을 높이고 천연 콜라겐 생성을 촉진하는 것으로 알려진 혁신적인 폴리뉴클레오티드 주입 치료인 필아트 바이 크로마(PhilArt by Croma)를 도입할 예정입니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 폴리뉴클레오티드 주사제 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인의 분석
  • 시장 성장 억제요인의 분석
• 폴리뉴클레오티드 주사제 시장 : 분석 툴
  • 업계 분석 : Porter의 산업 분석
  • PESTEL 분석

제4장 폴리뉴클레오티드 주사제 시장 : 용도별 추정과 동향 분석

• 시장 점유율 : 용도별(2024년·2030년)
• 부문 대시보드
• 세계의 폴리뉴클레오티드 주사제 시장 전망 : 용도별
• 시장 규모 예측과 동향 분석(2018-2030년)
  • 눈
  • 입술
  • 이마
  • 턱선 및 광대뼈
  • 기타

제5장 폴리뉴클레오티드 주사제 시장 : 최종 용도별 추정과 동향 분석

• 시장 점유율 : 최종 용도별(2024년·2030년)
• 부문 대시보드
• 세계의 폴리뉴클레오티드 주사제 시장 전망 : 최종 용도별
• 시장 규모 예측과 동향 분석(2018-2030년)
  • 메디컬 스파
  • 미용·코스메틱 센터
  • 병원

제6장 폴리뉴클레오티드 주사제 시장 : 지역별 추정과 동향 분석

• 시장 점유율 분석 : 지역별(2024년·2030년)
• 시장 대시보드 : 지역별
• 세계 시장 스냅숏 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 최신 동향과 영향 분석 : 주요 시장 참여 기업별
• 기업/경쟁의 분류
• 벤더 구도
  • 주요 유통업체·채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2024년)
  • PHARMA RESEARCH
  • BIOPLUS CO., LTD.
  • LG Chem
  • AMEELA
  • Mastelli
  • Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
  • Promoitalia Laboratories
  • Fox Pharma
  • BR Pharm
  • DermFocus

KSA

영문 목차

영문목차

Polynucleotides Injectable Market Size & Trends:

The global polynucleotides injectable market size was estimated at USD 127.6 million in 2024 and is projected to grow at a CAGR of 15.1% from 2025 to 2030. Technological advancements in biotechnology primarily drive market growth, as do the increasing demand for skin rejuvenation, personalized medicine, and investments in research and development (R&D). According to an article published by PMTA Journal in March 2024, polynucleotide injections gained prominence in aesthetic medicine due to their beneficial effects on skin, hair, and other tissues, as explored in this comprehensive review.

The growing demand for advanced skin rejuvenation treatments is a primary driver of the polynucleotides injectable industry. As individuals seek more effective solutions to address signs of aging, such as fine lines, wrinkles, and skin laxity, the interest in novel injectable treatments such as polynucleotides has surged. For instance, a recent study published in the journal Dermatologic Therapy found that polynucleotide injections improved skin tone, fine lines, skin elasticity, and hydration in patients in their 30s and 40s.

The increasing focus on personalized medicine also contributed to the growth of the market. As healthcare providers and patients alike seek customized approaches to skin rejuvenation, polynucleotides' ability to stimulate the body's natural collagen production and cellular regeneration has made them a popular choice. This trend is particularly evident in the rising demand for personalized aesthetic treatments, which is expected to continue expanding the market.

Finally, integrating innovative technologies, such as digital imaging and automated injection systems, has further propelled the polynucleotides injectable industry. These advancements improved polynucleotide injections' precision, consistency, and safety, making them more appealing to healthcare providers and patients. As the aesthetic industry continues to evolve, incorporating cutting-edge technologies is expected to remain a vital driver of the polynucleotide injectable industry. For instance, in 2022, Pulse Light Clinic in London is introducing PhilArt by Croma, an innovative polynucleotide injection treatment recognized for significantly enhancing skin hydration, boosting elasticity, and stimulating natural collagen production - a pioneering advancement in skin rejuvenation.

Global Polynucleotides Injectable Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global polynucleotides injectable market report based on application, end-use, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Eyes
• Lips
• Forehead
• Jawline & Cheekbones
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• MedSpas
• Aesthetic & Cosmetic Centers
• Hospitals
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Polynucleotides Injectable Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements
    • 3.2.1.2. Growing demand for skin rejuvenation
    • 3.2.1.3. Shifting focus towards regenerative aesthetics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited access to the treatments
• 3.3. Polynucleotides Injectable Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Polynucleotides Injectable Market: Application Estimates & Trend Analysis

• 4.1. Application Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Polynucleotides Injectable Market by Application Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Eyes
    • 4.4.1.1. Eyes market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Lips
    • 4.4.2.1. Lips market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Forehead
    • 4.4.3.1. Forehead market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Jawline & Cheekbones
    • 4.4.4.1. Jawline & Cheekbones market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Polynucleotides Injectable Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Polynucleotides Injectable Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. MedSpas
    • 5.4.1.1. MedSpas market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Aesthetic & Cosmetic Centers
    • 5.4.2.1. Aesthetic & cosmetic centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Hospitals
    • 5.4.3.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Polynucleotides Injectable Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. North America
  • 6.5.2. U.S.
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe
  • 6.6.2. UK
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Denmark
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.9. Norway
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory framework
    • 6.6.9.3. Competitive scenario
    • 6.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Asia Pacific
  • 6.7.2. Japan
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. China
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. India
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. Australia
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. South Korea
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.7. Thailand
    • 6.7.7.1. Key country dynamics
    • 6.7.7.2. Regulatory framework
    • 6.7.7.3. Competitive scenario
    • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Latin America
  • 6.8.2. Brazil
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. MEA
  • 6.9.2. South Africa
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. UAE
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key country dynamics
    • 6.9.5.2. Regulatory framework
    • 6.9.5.3. Competitive scenario
    • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. PHARMA RESEARCH
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Others benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. BIOPLUS CO., LTD.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Others benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. LG Chem
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Others benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. AMEELA
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Others benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Mastelli
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Others benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Others benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Promoitalia Laboratories
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Others benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Fox Pharma
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Others benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. BR Pharm
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Others benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. DermFocus
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Others benchmarking
    • 7.3.13.4. Strategic initiatives

관련자료